Management of Residual Retroperitoneal Mass After BEP Chemotherapy

Rationale for Surgical Intervention

The European Society for Medical Oncology recommends that residual masses after chemotherapy frequently contain viable malignant germ cell tumor or mature teratoma, both of which require surgical excision 1
The standard approach for nondysgerminomatous germ cell tumors is complete surgical resection of all visible residual masses when markers have normalized, as suggested by the European Society for Medical Oncology 2
Mixed germ cell tumors require more aggressive surgical management due to the teratomatous component that does not respond to chemotherapy, according to the European Society for Medical Oncology 1

Complete retroperitoneal lymph node dissection of the residual conglomerate mass with clear margins is recommended by the European Society for Medical Oncology 1
Exploration of the entire abdominal cavity to identify any additional disease is suggested by the National Health Service, based on guidelines from the British Journal of Cancer 3
The surgery should be performed by a team experienced in oncologic surgery with multidisciplinary capabilities, as recommended by the National Health Service, based on guidelines from the British Journal of Cancer 3

If complete resection reveals only necrosis/fibrosis or mature teratoma: no additional chemotherapy is needed, proceed to surveillance, as suggested by the European Society for Medical Oncology 1, 2
If viable malignant germ cell tumor is found but completely resected: consider 1-2 additional cycles of BEP as consolidation, according to the European Society for Medical Oncology 2
If viable tumor with incomplete resection or multiple sites: salvage chemotherapy with alternative regimens (TIP or VIP) should be initiated, as recommended by the European Society for Medical Oncology 4

Measure tumor markers weekly to ensure they remain normal or continue declining, as suggested by the European Society for Medical Oncology 2
If tumor markers begin rising before surgery, this indicates progressive disease requiring immediate salvage chemotherapy rather than surgery, according to the European Society for Medical Oncology 2
Repeat imaging is only justified if there will be a delay in surgical scheduling, not as a substitute for resection, as recommended by the European Society for Medical Oncology 1

The European Association of Urology recommends that retroperitoneal lymph node dissection (RPLND) is the established standard for residual masses >10mm after chemotherapy with normal markers 5, 6
The American Society of Clinical Oncology notes that residual masses frequently contain viable malignant germ cell tumor or mature teratoma, both requiring surgical excision 5

The National Comprehensive Cancer Network recommends imaging surveillance with CT chest/abdomen/pelvis every 6-8 weeks for the first 6 months, then every 3 months for year 2, and then every 6 months through year 5 5
The European Society for Medical Oncology suggests tumor marker monitoring weekly for the first 3 months, then every 3-4 months for year 1-2, and then every 6 months for years 3-5 7, 8

The American Society of Clinical Oncology states that immediate salvage chemotherapy is required if tumor markers begin rising, residual mass increases in size on imaging, or new lesions appear 5, 6, 9
The European Association of Urology recommends reconsidering surgery if the patient changes their mind about surgical intervention or if the mass remains stable but the patient develops symptoms 5, 6

The National Comprehensive Cancer Network suggests that standard salvage regimens include TIP (paclitaxel, ifosfamide, cisplatin) for 4 cycles, VIP (etoposide, ifosfamide, cisplatin) for 4 cycles, or VeIP (vinblastine, ifosfamide, cisplatin) for 4 cycles 5, 9

The European Society for Medical Oncology emphasizes that surveillance is NOT equivalent to surgery in terms of cure rates and that delayed surgery may be more extensive and have worse outcomes 5, 6